CO_favicon

Caravel Oculus

2026.7.17

Caravel Oculus Advances Novel Corneal Drug CA201A Globally with Phase II Trial Recruitment in Australia

2025.6.5

Our company convened the 2025 annual shareholders’ meeting

PIPELINE

Drawing on years of clinical experience, a group of ophthalmology professors observed that certain existing drug compounds hold potential for further research and development in diseases with no current treatment options. This insight led them to explore additional product opportunities with strong development potential.

CONTACT US

Feel free to contact us
if you have any questions or comments.